# CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/ctx110-allogeneic-crispr-cas9-engineered-car-t-cells-in-patients-pts-with/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Joseph P. McGuirk,Constantine S. Tam,Nicolaus Kröger,Peter A. Riedell,Hemant S. Murthy,Phoebe Joy Ho,Joseph Maakaron,Edmund K. Waller,Farrukh T. Awan,Paul Shaughnessy,Armin Ghobadi,Michael Bishop,Ana Alfonso Piérola,Michael Dickinson,Praveen Ramakrishnan Geethakumari,Ainsley Ross,William B. Stevens,Huansheng Xu,Anna Ma,Sarah Beaussant-Cohen,Richard T. Maziarz,Carlos Bachier |
| Citations | 57 |
| DOI | 10.1182/blood-2022-166432 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4310161875 |
| Type | conference-abstract |
| Year | 2022 |

## Paper authors

- [Ainsley Ross](https://scholariq.org/researchers/ainsley-ross/)

## Paper journal

- [Blood](https://scholariq.org/journals/blood/)

## Paper primary topic

- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Paper topics

- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.